Entera Bio announced the appointment of Rachel Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board, SAB. Dr. Wagman brings more than 20 years of metabolic bone disease and women’s health research and drug development experience to Entera.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTX:
- Entera Bio to present Phase 1 data from EB612 at ENDO 2024
- Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
- Entera Bio Releases Crucial Financial Information Update
- Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
- Biotech Alert: Searches spiking for these stocks today